Table 3. Adjusted risk factors for polypharmacy in participants.
| Adjusted Prevalence Ratios (95% CI) | |||
|---|---|---|---|
| Overall | HIV Positive | HIV Negative | |
| HIV status | |||
| Positive | 1.36 (1.26 to 1.46) a | - | - |
| Negative | Referent | - | - |
| Age | |||
| ≥ 50 y | 1.61 (1.47 to 1.76) a | 1.22 (1.13 to 1.33) a | 1.56 (1.32 to 1.84) a |
| < 50 y | Referent | Referent | Referent |
| Race/ethnicity | |||
| Non-Hispanic black | 0.73 (0.65 to 0.82) a | 0.83 (0.74 to 0.92) a | 0.94 (0.77 to 1.16) |
| Other | 0.86 (0.75 to 0.99) a | 1.04 (0.93 to 1.16) | 0.82 (0.63 to 1.08) |
| Non-Hispanic white | Referent | Referent | Referent |
| Medication insurance coverage | |||
| Yes | 1.32 (1.16 to 1.49) a | 1.14 (1.01 to 1.27) a | 1.90 (1.59 to 2.28) a |
| No | Referent | Referent | Referent |
| Enrollment period | |||
| Early recruitment (1987–1991) | 1.26 (1.14 to 1.40) a | 1.08 (0.99 to 1.18) a | 1.42 (1.18 to 1.72) a |
| Late recruitment (2001–2003) | Referent | Referent | Referent |
| Viral Load | - | - | |
| Detectable | - | 0.97 (0.92 to 1.02) | - |
| Undetectable | - | Referent | - |
| CD4+ count (cells/mm3) | |||
| < 500 | - | 0.97 (0.91 to 1.02) | - |
| ≥ 500 | - | Referent | - |
| ART adherence | |||
| 95%-99% | - | 1.04 (0.99 to 1.10) | - |
| 75%-94% | - | 0.98 (0.89 to 1.09) | - |
| <75% | - | 0.95 (0.80 to 1.14) | - |
| 100% | - | Referent | - |
| ART medication use | - | 1.15 (1.12 to 1.18) a | - |
Abbreviation: ART, antiretroviral therapy; a Statistically significant; p values were calculated using generalized estimating equation models.